New pill aims to cut Parkinson's 'OFF' episodes in major trial
Disease control
Ongoing
This Phase 3 study tests an experimental drug called CVN424 in 330 people with Parkinson's disease who experience motor complications. Participants take either 75 mg, 150 mg, or a placebo pill once daily for 12 weeks. The main goal is to see if CVN424 can reduce the daily hours o…
Phase: PHASE3 • Sponsor: Cerevance • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC